| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Dividendenbekanntmachungen (02.04.2026) | 8.841 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,29 USD 0,2501 EUR AKTIA BANK PLC FI4000058870 - 0,8 EUR ALICO INC US0162301040 0,05 USD 0,0431... ► Artikel lesen | |
| Do | Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights | 1.370 | Business Wire | Regulatory News:
Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.
2025 business... ► Artikel lesen | |
| Do | Pharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 1.301 | GlobeNewswire (Europe) | Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline for submission of NDA dossier of deucrictibant... ► Artikel lesen | |
| Do | Resverlogix Corp.: Resverlogix Corp. Announces Issuance of MCTO by ASC | 530 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the... ► Artikel lesen | |
| Do | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | 491 | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| Do | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering | 439 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| Do | OS Therapies: OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors | 418 | Newsfile | Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately $2 million in non-dilutive R&D tax credits... ► Artikel lesen | |
| 08:00 | NurExone baut US-Standbein aus - Exo-Top rückt in den strategischen Fokus | Small- & Micro Cap Investment | |||
| 09:10 | NEC Corporation: Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer | 375 | JCN Newswire | Strasbourg, France & Schiphol, Netherlands, Apr 3, 2026 - (JCN Newswire) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment... ► Artikel lesen | |
| Do | TriNetX, LLC.: TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions | 304 | PR Newswire | Under the collaboration, TriNetX will provide Regeneron with secure, licensed access to TriNetX's current and future de-identified health data from approximately 300 million individuals (170 million... ► Artikel lesen | |
| Do | NanoRepro beruft neuen Vorstand und startet Strategie-Review | 288 | 4investors | Die NanoRepro AG hat Mike Eckel mit Wirkung zum 1. Oktober 2026 in den Vorstand berufen. Er folgt auf Stefan Pieh, dessen Vertrag Ende Februar 2026 ausgelaufen war. Eckel war zuletzt als Abteilungsleiter... ► Artikel lesen | |
| 07:06 | Innate Pharma SA: Innate Pharma to Participate in the Kempen Life Sciences Conference | 259 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 11:10 | Evotec-Aktie: Neuzugang könnte neue Hoffnungen wecken | 257 | sharedeals.de | Die Evotec-Aktie blieb in der schwachen Phase der Börsen stabil und konnte sich entgegen dem Trend leicht erholen. Am Donnerstag ging sie mit einem Gewinn von +2,2% aus dem Handel und steht bei rund... ► Artikel lesen | |
| Do | Dermata Therapeutics: Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System | 252 | ACCESS Newswire | - This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US, Australia... ► Artikel lesen | |
| Do | Regeneron Pharmaceuticals, Inc.: EYLEA HD (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) | 251 | GlobeNewswire (Europe) | Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing regimen... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| SIGA TECHNOLOGIES | 5,250 | 0,52 | +9,90 % | 0,60 | 07.04.2026 | |
| BB BIOTECH | 47,850 | 2,47 | +5,16 % | 2,25 | 23.03.2026 | |
| CSL | 84,23 | 2,61 | +3,10 % | 1,84 | 10.03.2026 | |
| AMGEN | 301,50 | 8,32 | +2,76 % | 2,52 | 15.05.2026 | |
| RECORDATI | 48,620 | 1,30 | +2,67 % | 0,71 | 18.05.2026 | |
| NOVONESIS | 51,64 | 0,87 | +1,68 % | 4,25 | 20.03.2026 | |
| SINO BIOPHARM | 0,698 | 0,01 | +1,43 % | 0,05 | 24.06.2026 | |
| GENUS | 27,600 | 0,38 | +1,38 % | 0,11 | 05.03.2026 | |
| BIOMERIEUX | 92,60 | 0,90 | +0,97 % | 0,98 | 09.06.2026 | |
| BIO-TECHNE | 45,800 | 0,27 | +0,59 % | 0,08 | 13.02.2026 |